Social Determinants of Health and Long-Term Engagement in Schizophrenia Care

This episode, titled "Social Determinants of Health and Long-Term Engagement in Schizophrenia Care," features panelists Dr. John Kane and Mark Jankelow exploring two interconnected challenges: the outsized role of social determinants in schizophrenia outcomes and the practical difficulties of sustaining long-term patient engagement.

Dr. Kane opens by affirming that social determinants — including socioeconomic status, housing instability, food insecurity, childhood trauma, and parental psychopathology — likely account for a greater share of health outcomes than medical factors alone. He acknowledges the complexity of these issues, noting that while clinicians cannot always change a patient's circumstances, they must understand and account for them in treatment planning. He also highlights the bidirectional relationship between homelessness and mental illness, underscoring the need for far greater systemic attention to these factors.

Mark Jankelow then illustrates the real-world consequences of disengagement through a vivid clinical scenario: a relatively stable patient who misses appointments, is hospitalized without his outpatient providers being notified, has his medications changed without continuity of care, and is discharged without a clear follow-up plan. Without a proactive family member or power of attorney to bridge the gap, the patient returns to the community, begins using cannabis, and rapidly relapses. Mark points to fragmented communication between inpatient and outpatient providers as a critical failure point, and notes that patients discharged on oral medications are particularly vulnerable, often discontinuing within days.

The segment closes with the panel discussing the importance of having dedicated care coordinators who proactively track and follow up with patients who disengage, while acknowledging that many practices lack the staffing or bandwidth to do so consistently.

In the next episode, "Navigating the Schizophrenia Treatment Landscape: Antipsychotic Mechanisms and Evolving Options," panelists will provide a comprehensive overview of first, second, and third generation antipsychotics, examining their mechanisms of action, efficacy, and side effect profiles while highlighting the ongoing need for new treatment approaches and better implementation of existing evidence.